Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
Abstract Background Abiraterone is an important agent in the treatment of advanced prostate cancer. Early changes in prostate-specific antigen while on abiraterone in patients with metastatic castrate-resistant prostate cancer potentially have financial and health implications for patients. Limited...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2019-05-01
|
| Col·lecció: | BMC Cancer |
| Matèries: | |
| Accés en línia: | http://link.springer.com/article/10.1186/s12885-019-5729-7 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|